Hisamitsu Pharmaceutical Co., Ltd, a subsidiary of Hisamitsu Pharmaceutical Co., Inc., is a Taiwanese company located in Taipei. The firm manufactures and markets pharmaceuticals.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

Operates a biomedical group

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxonin for bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.

The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. Department of Defense (DoD). The institute is centered at the Forest Glen Annex, part of the unincorporated Silver Spring urban area in Maryland just north of Washington, DC, but it is a subordinate unit of the U.S. Army Medical Research and Development Command (USAMRDC), headquartered at nearby Fort Detrick, Maryland. At Forest Glen, the WRAIR has shared a laboratory and administrative facility — the Sen Daniel K. Inouye Building, also known as Building 503 — with the Naval Medical Research Center since 1999.

Part of Kitasato University, The Kitasato Institute is a company headquartered in Tokyo, Japan, that operates a research institution.

Kitasato Daiichi Sankyo Vaccine Co., Ltd., a subsidiary of Daiichi Sankyo Co., Ltd., is a company headquartered in Kitamoto, Japan. The firm develops, manufactures and distributes vaccines. It was acquired by Daiichi Sankyo Co., Ltd. from The Kitasato Institute on November 30, 2017.

Panacea Biotec is an Innovation driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals, Vaccines and Biosimilars. Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited with a commitment to make Innovative Products Affordable and Accessible to the masses. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd. Panacea Biotec is witnessing a period of expansion across every aspect of their business from innovative products to customers in market, from manufacturing to regulatory approvals and thereby laying the foundation for translation of their vision in becoming greatest, largest and most admired biotechnology company in the World by 2020. Ardent Research and Development efforts have always been a great strength of Panacea Biotec. The main research areas are New Chemical Entities (NCE), New Biological Entities (NBE) Novel Drug Delivery System (NDDS) based pharmaceutical formulations, Novel peptides & human monoclonal antibodies and Vaccine development. The company has developed four distinguished, ultra-modern, state-of-art R&D centres in different locations, having internal capabilities for constant research, with over 300 highly professional and skilled scientists engaged in various aspects of research.

The Chemo-Sero Therapeutic Research Institute operates as a pharmaceutical company specializing in the field of biotechnology, immunology, hematology, and microbiology. It develops and manufactures vaccines and blood plasma products. The firm's products include human and veterinary vaccines, diagnostic antigens, and treatments for congenital disorders. They also provides newborn screening tests and quality assurance systems solutions. The company was founded on December 26, 1945 and is headquartered in Kumamoto, Japan.

Liaoning Chengda Biotechnology Co., Ltd. is an international advanced virus vaccine production technology platform introduced from the United States. It was established in Shenyang in June 2002 as a high-tech enterprise. Companies adhering to the "integrity integrity, benevolence and harmony" of the core values, is committed to research and development, production and promotion of "international level, domestic leading" biological products, the main products for Chengda speed up human rabies vaccine and Chengda Libao people type B Encephalitis inactivated vaccine. Chengda Bio was listed on the New Third Board on December 31, 2014 with a registered capital of 360 million. It is controlled by Liaoning Chengda Co., Ltd. (600739), and its profitability and appreciation potential are among the top three new board companies. The production base is located in the National High-tech Park of Weinan, Shenyang, covering an area of ​​nearly 100 acres, with a construction area of ​​over 50,000 square meters and more than 800 employees. There are 4 stock solutions workshops, 3 preparation workshops and a pilot plant. The annual production capacity of human rabies vaccine reaches 10 million, and the annual production capacity of Japanese encephalitis vaccine is 10 million. All workshops have successfully passed the 2010 national new GMP certification. Chengda Bio is a family vaccine manufacturer. Chengda Suida rabies vaccine has always maintained a leading position in the domestic market, and has been exported to India, Pakistan, Thailand, the Philippines, Kenya, Ghana, Malawi, Georgia, etc. Countries. Chengda Libao JE vaccine is currently the only inactivated Japanese encephalitis vaccine in China and has been successfully exported to Thailand and registered in Cambodia. The bivalent renal syndrome hemorrhagic fever vaccine (Vero cells) independently developed based on the core technology platform has completed clinical research work, and the target is to obtain the production batch number in 2022 and pass the GMP acceptance. On the one hand, Chengda Bio has accelerated the expansion of its product line, supplemented the conventional vaccine varieties at a high starting point, and actively promoted the development of multi-linked multi-valent vaccines and innovative vaccines around the country's expansion of the immunization program vaccine supply system. Chengda Bio has always adhered to the values ​​of “integrity and responsibility”, established brand awareness and reputation in both domestic and international markets, adhered to the “international level, domestic leading” product positioning, and strived to become trustworthy and respectful in the industry. A company with significant influence.

Chengdu Institute of Biological Products is a developing and manufacturing bases of biological products in China. It engages in research of medical microbiology, cytology and immunology, producing and marketing biological products such as prophylactic products, plasma-derived products, diagnostic reagents. The company was founded in 1953 and is headquartered in Sichuan, CN.

Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine. With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.

Wuhan Institute of Biological Products Co., Ltd. is a Chinese company located in Wuhan and ultimately controlled by the Government of China that develops vaccines and immunization products.

Sanofi Pasteur SA develops, manufactures, and supplies vaccines in France and internationally. The company provides vaccines for bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. It has production sites in France, the United States, Canada, China, Thailand, and Argentina. The company was formerly known as Aventis Pasteur S.A. and changed its name to Sanofi Pasteur SA in 2004. The company was founded in 1990 and is headquartered in Lyon, France. The company is headquartered in Lyon, France. Sanofi Pasteur SA operates as a subsidiary of Sanofi-Aventis.

The high-end vaccine is a biotech new drug company that develops and mass-produces vaccines and biological agents. It uses cell culture technology and develops viral vaccines and biosimilar drugs through the International Cooperation Alliance. Based on Taiwan, the company will give priority to Taiwan's demanded products as the development target, providing innovative medical products to protect the health and safety of the whole people. At the same time, we hope to become a research and development and mass production center in the Asia-Pacific region, and then look to the world to protect all human beings from the threat of many diseases.

Nippon Zoki Pharmaceutical Co. Ltd. is a private company headquartered in Chuo-ku, Japan, that manufactures pharmaceutical products.

ZEON Corp. engages in the production and sale of synthetic rubbers and specialty plastics. It operates through the following segments: Elastomer Materials Business, Specialty Materials Business, and Others. The Elastomer Materials Business segment includes synthetic rubbers used in automobile tires and conveyer belts; synthetic lattices used in tires and adhesives; and chemical products such as resins and inks. The Specialty Materials Business segment comprises of synthetic aroma chemicals and other industrial chemicals; information and imaging materials; specialty plastics for optical lenses; and medical products. The Others segment consists of paints, butadiene extraction technology, and reaction injection molding (RIM) formulations and products. The company was founded on April 12, 1950 and is headquartered in Tokyo, Japan.

Hunan Zhongan Bio-Pharmaceutical Co., Ltd. (doing business as Zhongan Bio-Pharmaceutical Co. Ltd.), part of Tianjin Ringpu Bio-technology Co., Ltd., is a Chinese company located in Changsha that produces bacterial vaccine. It was acquired by Tianjin Ringpu Bio-technology Co., Ltd. from Hunan Yatai Biological Development Co., Ltd. on May 06, 2011 for $2.58 million.

Livzon Group Vaccine Engineering Co., Ltd., established on 2010-09-27, The scope of business includes technical research on biomedical products and vaccines,to develop.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)